774212-79-2

Usage

Uses

Used in Pharmaceutical Synthesis:
(1R,3S)-1-(Boc-amino)-3-(Cbz-amino)cyclopentane is used as a building block for the preparation of various pharmaceuticals and bioactive compounds. Its unique structure and protective groups allow for the synthesis of complex molecules with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, (1R,3S)-1-(Boc-amino)-3-(Cbz-amino)cyclopentane is used as a valuable intermediate. Its versatile reactivity and functional groups enable the creation of a wide range of chemical compounds for research and industrial purposes.

Upstream product

• 100-51-6 benzyl alcohol 
• 261165-05-3 (1S,3R)-3-(tert-butoxycarbonylamino)cyclopentanecarboxylic acid 

Downstream Products

• 1257045-86-5 (1S,3R)-(3-amino-cyclopentyl)carbamic acid benzyl ester 
• 774212-81-6 ((1R,3S)-3-amino-cyclopentyl)-carbamic acid tert-butyl ester 
• 1418200-24-4 (R)-1-(6-benzenesulfonyl-1-[(1S,3R)-3-(2,2-difluoro-ethylamino)-cyclopentyl]-1,6-dihydro-1,3,5,6-tetraaza-as-indacen-2-yl)-ethanol 
• 1418200-23-3 (R)-1-(6-benzenesulfonyl-1-[(1S,3R)-3-(2,2,2-trifluoro-ethylamino)-cyclopentyl]-1,6-dihydro-1,3,5,6-tetraaza-as-indacen-2-yl)-ethanol 
• 1418200-22-2 (R)-1-[1-((1S,3R)-3-amino-cyclopentyl)-6-benzenesulfonyl-1,6-dihydro-1,3,5,6-tetraaza-as-indacen-2-yl]-ethanol 
• 1418200-21-1 ((1R,3S)-3-[6-benzenesulfonyl-2-((R)-1-hydroxyethyl)-6H-1,3,5,6-tetraaza-as-indacen-1-yl]-cyclopentyl)-carbamic acid tert-butyl ester 
• 1418200-43-7 [(1R,3S)-3-(5-amino-1-benzenesulfonyl-1H-pyrrolo[2,3-b]pyridin-4-ylamino)-cyclopentyl]-carbamic acid tert-butyl ester 
• 1315495-85-2 [(1R,3S)-3-( 1-benzenesulfonyl-5-nitro-1H-pyrrolo[2,3-b]pyridin-4-ylamino)-cyclopentyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE

The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).

POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE

The present disclosure is directed to compounds of Formula (I) as Bruton's kinase inhibitors and their preparation, as well as compositions comprising compounds of Formula (I).

1,3-DISUBSTITUTED CYCLOPENTANE DERIVATIVES

Compounds of the formula (I) in which R, Y, R1, X1, X2, X3 and q have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

FUSED TRICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF JANUS KINASES

The invention provides novel compounds of formula (I) having the general formula (I) wherein R1, V, W, X, Y and Z are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.

SELECTIVE KINASE INHIBITORS

Provided are pyrimidine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

PYRIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS FOR TREATING DISEASES RELATED TO MCH RECEPTOR

The present invention encompasses novel substituted pyridine compounds of Formula (I), which act as MCH receptor antagonists. These compositions and pharmaceutical compositions thereof are useful in the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF

The present invention relates to novel compounds of Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.